Imipenem/Cilastatin Teva

Imipenem, the active ingredient in Imipenem/Cilastatin Teva, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous or inhalation use. It treats severe bacterial infections such as complicated intra‑abdominal, urinary tract, skin, and respiratory infections in hospitalized adults.

GNH USA supplies Imipenem/Cilastatin Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/Cilastatin is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: provides bacterial eradication and clinical cure in mixed aerobic‑anaerobic infections. - Complicated urinary tract infections: eliminates resistant uropathogens to achieve microbiological clearance. - Skin and soft‑tissue infections: treats severe cellulitis and wound infections caused by susceptible organisms. - Bacterial pneumonia: delivers rapid bactericidal activity against common respiratory pathogens. - Febrile neutropenia: offers empiric coverage for high‑risk neutropenic patients with suspected infection.

Adverse reactions may occur with any antimicrobial therapy and should be monitored.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Headache - Infusion‑site phlebitis - Elevated liver enzymes

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment - Anaphylactic or severe allergic reactions - Clostridioides difficile‑associated colitis - Acute renal toxicity - Thrombocytopenia - Neutropenia

Use of Imipenem/Cilastatin requires careful assessment of patient risk factors and clinical monitoring. - Renal function assessment: adjust dose in patients with reduced creatinine clearance. - Seizure risk: avoid in patients with a history of seizures or CNS disorders. - Hypersensitivity: discontinue if signs of an allergic reaction appear. - Elderly patients: monitor for neurotoxicity and renal changes. - Concomitant valproic acid: anticipate reduced seizure control. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Imipenem/Cilastatin can interact with several medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may reduce antiepileptic effect, increasing seizure risk. - Probenecid: can raise imipenem plasma levels, heightening toxicity. - Cyclosporine: increased neurotoxic potential.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate renal impairment. - NSAIDs: potential additive nephrotoxicity. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Aminoglycosides: increased risk of nephro‑ and ototoxicity.